Disclosure Plus

Exchange: "Icure Pharmaceutical Incorporation's Remedial Period Ends… Notice on Delisting Decision"

Shin Ha-yeon
2026-07-13 17:45:44
[E-Daily Reporter Shin Ha-yeon ] The KOSDAQ Market Division of the Korea Exchange announced on the 13th that the eight-month improvement period for Icure Pharmaceutical Incorporation(175250)had ended as of the 12th.
The exchange stated, “The company must submit a report on the implementation of its improvement plan and a verification report from an expert regarding the results of the plan’s implementation within 15 business days of the end of the improvement period. The exchange plans to convene the Corporate Review Committee within 20 business days of the submission of these documents to decide whether to delist the company.”
If the company files an appeal, the KOSDAQ Market Committee will convene within 20 business days of receiving the appeal to decide on delisting (including whether to grant a remediation period).

Economy

Corporation

IT·Science

Economy

[VC's Pick] Big Money Flows into Smart 'Medical AI and Robotics' Technologies That Replace Human Hands

This week (November 16–20), startups in various fields—including robotics, image analysis, and business platforms—secured investments from venture capital (VC) firms and accelerators (ACs). In particu…
2026-11-21 10:04:03

Corporation

Celltrion Sees Full-Scale Results from Direct Sales in the U.S. … “Projected Operating Profit of 2.4 Trillion Won Next Year”

Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
2026-11-21 06:01:02

IT·Science

Penetrium Bioscience and AprilBio Rally as AriBio-Linked Stocks Diverge [K-Bio Pulse]

South Korean pharmaceutical and biotechnology stocks posted mixed results on November 19, driven by clinical trial developments and expectations regarding their inclusion in major stock indices. Penet…
2026-11-21 08:17:02